Browse > Article
http://dx.doi.org/10.3339/jkspn.2014.18.2.98

The Use of Nafamostat Mesilate as an Anticoagulant during Continuous Renal Replacement Therapy for Children with a High Risk of Bleeding  

Lee, Sang Taek (Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine)
Cho, Heeyeon (Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine)
Publication Information
Childhood Kidney Diseases / v.18, no.2, 2014 , pp. 98-105 More about this Journal
Abstract
Purpose: Nafamostat mesilate (NM), a synthetic serine protease inhibitor, has been investigated as an anticoagulant for adult patients with a high risk of bleeding, who need chronic renal replacement therapy (CRRT). However, little is known about the use of NM as an anticoagulant in pediatric CRRT. The aim of this study was to evaluate the ideal dosage, efficacy, and safety of NM in pediatric CRRT. Methods: We conducted a retrospective study of 40 pediatric patients who had undergone at least 24 h of venovenous CRRTs between January 2011 and October 2013. We divided the patients according to risk of bleeding. Those at high risk received no anticoagulation (group 1) or NM as an anticoagulant (group 2), while those at low risk received heparin (group 3). Results: Forty patients (25 male and 15 female; mean age, $8.2{\pm}6.6$ years) were enrolled. The mean duration of CRRT was 13.0 days, and the survival rate was 57.5%. The mean hemofilter lifespan was 39.3 h in group 1 and 11.3 h in group 3. In group 2, hemofilter lifespan was extended from 7.5 h to 27.4 h after the use of NM (P =0.001). The mean hemofilter lifespan with NM was greater than with heparin (P =0.018). No patient experienced a major bleeding event during treatment with NM. Conclusion: NM may be a good alternative anticoagulant in pediatric patients with a high risk of bleeding requiring CRRT, and is not associated with bleeding complications.
Keywords
Nafamostat mesilate; Continuous renal replacement therapy; Children; Bleeding risk;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Ronco C, Brendolan A, Bragantini L, Chiaramonte S, Feriani M, Fabris A, et al. Treatment of acute renal failure in newborns by continuous arteriovenous hemofiltration. Kidney Int 1986;29:908-15.   DOI   ScienceOn
2 Scott M, Sutherland, Steven R, Alexander. Continuous renal replacement therapy in children. Pediatr Nephrol 2012;27:2007-16.   DOI   ScienceOn
3 Flynn JT. Choice of dialysis modality for management of pediatric acute renal failure. Pediatr Nephrol 2002;17:61-9.   DOI   ScienceOn
4 Vasudevan A, Ivengar A, Phadke K. Modality of choice for renal replacement thepray for children with acute kidney injury: Results of a survey. Indian J Nephrol 2012;22:121-4.   DOI
5 Scott Walters, Craig Porter, Patrick D Brophy. Dialysis and pediatric acute kidney injury: choice of renal support modality. Pediatr Nephrol 2009;24:37-48.   DOI   ScienceOn
6 Michael Joannidis, Heleen M Oudemnas-van Straaten. Clinical review: Patency of the circuit in continuous renal replacement therapy. Critical Care 2007;11:218.   DOI
7 Baek NN, Jang HR, Huh W, Kim YG, Kim DJ, Oh HY, et al. The role of nafamostat mesylate in continuous renal replacement therapy among patients at high risk of bleeding. Ren Fail 2012;34:279-85.   DOI
8 R.L. Mehta. Anticoagulation in severely ill patients treated with continuous hemofiltration. Nefrologia 1992;12:287-94.
9 Hu ZJ, Iwama H, Suzuki R, Kobayashi S, Akutsu I. Time course of activated coagulation time at various site during continuous hemodiafiltration using nafamostat mesilate. Intensive Care Med 1999;25:524-7.   DOI   ScienceOn
10 Hiroma T, Nakamura T, Tamura M, Kaneko T, Komiyama A. Continuous venovenous hemofiltration in neonatal onset hyperammonemia. Am J Perinatol 2002;19:221-4.   DOI
11 Tolwani AJ, Wille KM. Anticoagulation for continuous renal replacement therapy. Semin Dial 2009;22:141-5.   DOI   ScienceOn
12 Davis H, Leslie G. Maintaining the CRRT circuit: non-anticoagulant alternatives. Aust Crit Care 2006;19:133-8.   DOI
13 Maruyama Y, Yoshida H, Uchino S, Yokoyama K, Yamamoto H, Takinami M, et al. Nafamostat mesilate as an anticoagulation during continuous veno-venous hemodialysis: a three-year retrospective cohort study. Int J Artif Organs 2011;34:571-6.   DOI
14 Davenport A. Alternatives to standard unfractionated heparin for pediatric hemodialysis treatments. Pediatr Nephrol 2012;27:1869-79.   DOI
15 Nagava M, Futamura M, Kato J, Niimi N, Fukuta S. Application of a new anticoagulant (Nafamostat mesilate) to control hemorrhagic complications during extracorporeal membrane oxygenation-a preliminary report. J Pediatr Surg 1997;32:531-5.   DOI   ScienceOn
16 Maruyama H, Miykawa Y, Gejyo F, Arakawa M. Anaphylactoid reaction induced by nafamostat mesilate in a hemodialysis patient. Nephron 1996;74:468-9.   DOI   ScienceOn
17 Kammerl MC, Schaefer RM, Schweda F, Schreiber M, Riegger GA, Kramer BK. Extracorporal therapy with AN 69 membranes in combination with ACE inhibiton causing severe anaphylactoid reactions:still a current problem? Clin Nephrol 2000;53:486-6.
18 Yamazato M, Mano R, Oshiro-Chinen S, Tomivama N, Sakima A, Ishida A, et al. Severe abdominal pain associated with allergic reaction to nafamostat mesilate in a chronic hemodialsysis patient. Intern Med 2002;41:864-66.   DOI
19 Muto S, Imai M, Asano Y. Mechanisms of hyperkalemia caused by nafamostat mesilate. Gen Pharmacol 1995;26:1627-32.   DOI   ScienceOn
20 Ookawara S, Tabei K, Sakurai T, Sakairi Y, Furuya H, Asano Y. Additional mechanisms of nafamostat mesilate-associated hyperkalemia. Eur J Clin Pharmacol 1996;51:149-51.   DOI
21 Higuchi N, Yamazaki H, Kikuchi H, Gejyo F. Anaphylactoid reaction induced by a protease inhibitor, nafamostat mesilate, following nine administrations in a hemodialysis patient. Nephron 2000;85:400-1.
22 Ohtake Y, Hirasawa H, Sugai T, Oda S, Shiga H. Matsuda K, Kitamura N. Nafamostat mesylate as anticoagulant in continuous hemofiltration and continuous hemidiafiltration. Contrib Nephrol 1991;93:215-7.   DOI
23 Kramer P, Wigger W, Rieger J, Matthaei D, Scheler F. Arteriovenous haemofilteration: A new and simple method for treatment of over-hydrated patients resistant to diuretics. Klin Wochenschr 1997;55:1121-2.
24 Yang JW, Han BG, Kim BR, Lee YH, Kim YS, Yu JM, et al. Superior outcome of nafamostat mesilate as an anticoagulant in patients undergoing maintenance hemodialysis with intracerebral hemorrhage. Ren Fail 2009;31:668-75.   DOI   ScienceOn